Objective:To evaluate the changes of T helper cells and β2MG in peripheral blood of the patients with multiple myeloma for investigating their correlation, the immunological significance, and clinical significance. Methods:T helper cells in peripheral blood of 31 patients with MM and 20 healthy donors were measured by the flow cytometry, and β2-MG was tested by turbidimetric immunoassay. Results:①The proportion of Th1 was significantly lower in stages II and III MM than that in controls, (8.24±1.25)%、(9.27±0.73)% VS (11.16±0.42)%(P<0.05); Th2 was significantly lower in stages III MM than that in controls and the stages I,(0.87±0.09)% VS (1.46±0.1)%、(1.7±0.26)%(P<0.01);Th1/Th2 was significantly higher in stages III MM than that in controls and the stages I and II,(11.47±0.75)% VS(8.04±0.41)%、(6.04±1.19)%、(7.68±1.41)%(P<0.05 or 0.01),others were not different from controls.② The proportion of Th1 was obviously lower in MM of relapsing stage than that in controls, (7.99±1.19)% VS(11.16±0.42)%,(P<0.05); Th2 was obviously lower in MM of relapsing stage and newly diagnosed than that in controls and stable stage, (1.02±0.12)%、(0.73±0.11)% VS(1.46±0.1)%、(1.5±0.22)%(P<0.05); Th1/Th2 was obviously higher in MM of relapsing stage and newly diagnosed than that in controls and stable stage,(10.75±0.96)%、(11.43±1.25)% VS (8.05±0.41)%、(6.94±1.16)%(P<0.05). ③ The proportion of Th2 negatively correlated withβ2MG (r=-0.376),Th1/Th2 positively correlated withβ2MG(r=0.525)(p<0.05). Conclusion:MM patients had a had a low level of Th1 and Th2 but a high lever of Thl/Th2, which was associated with clinical stages ,disease progression and prognosis of MM, also valule to guide treatment.%目的：检测多发性骨髓瘤（MM）患者外周血 Th1、Th2细胞数量和比例的变化，并研究其与血β2微球蛋白（β2-MG）是否具有相关性,探讨其T 辅助细胞免疫功能状态及临床意义。方法：流式细胞术(FCM)检测31例 MM 患者及20例健康志愿者外周静脉血 Th1、Th2细胞的比例并分析比较。采用免疫比浊法测定患者血清β2-MG 水平。结果：①.II、III 期 MM 患者 Th1细胞比例较对照组降低，为（8.24±1.25）%、（9.27±0.73）% VS（11.16±0.42）%（均 P<0.05）， MM 组间及 I 期与对照组间比较无统计学意义；III 期 MM 患者 Th2细胞比例较对照组及 I 期降低，为（0.87±0.09）% VS（1.46±0.1）%、（1.7±0.26）%（均 P<0.01），其余组间及与正常对照间比较无统计学意义；III 期 MM 患者 Th1/Th2比值较对照组、I 及 II 期增高，为（11.47±0.75）% VS（8.04±0.41）%、（6.04±1.19）%、（7.68±1.41）%（P<0.05或0.01）。②化疗后复发组 MM 患者 Th1细胞比例较对照组降低，为（7.99±1.19）% VS（11.16±0.42）%，（P<0.05），其余组间及与对照组间比较无统计学意义；初诊组及化疗后复发组 MM 患者 Th2细胞比例较对照组及稳定期组降低，为（1.02±0.12）%、（0.73±0.11）% VS（1.46±0.1）%、（1.5±0.22）%（均 P<0.05）；初诊组及化疗后复发组 MM 患者 Th1/Th2比值较对照组及化疗后稳定组增高，为（10.75±0.96）%、（11.43±1.25）% VS （8.05±0.41）%、（6.94±1.16）%（均 P<0.05）。③MM 患者 Th2细胞与β2MG 呈负相关（r=-0.376），Th1/Th2比值与其呈正相关（r=0.525）(p<0.05)。结论：MM 患者外周血 T 辅助细胞亚群存在异常，Th1、Th2细胞比例降低及 Th1/Th2比值增高与临床分期、疾病进展及预后相关，对指导治疗也有一定的价值。
展开▼
